Exelixis, Inc. (LON:0IJO)
45.07
+1.25 (2.85%)
At close: Jun 24, 2025
Exelixis Revenue
Exelixis had revenue of $555.45M USD in the quarter ending March 31, 2025, with 30.62% growth. This brings the company's revenue in the last twelve months to $2.30B, up 24.49% year-over-year. In the year 2024, Exelixis had annual revenue of $2.17B with 18.49% growth.
Revenue (ttm)
$2.30B
Revenue Growth
+24.49%
P/S Ratio
5.14
Revenue / Employee
$2.00M
Employees
1,147
Market Cap
9.15B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.17B | 338.49M | 18.49% |
Dec 31, 2023 | 1.83B | 219.15M | 13.60% |
Dec 31, 2022 | 1.61B | 176.09M | 12.27% |
Dec 31, 2021 | 1.43B | 447.43M | 45.31% |
Dec 31, 2020 | 987.54M | 19.76M | 2.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Indivior | 905.57M |
Exelixis News
- 1 day ago - Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment - Seeking Alpha
- 1 day ago - Exelixis jumps on phase 3 data for zanzalintinib in colorectal cancer - Seeking Alpha
- 1 day ago - Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars - Benzinga
- 1 day ago - Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars - Benzinga
- 1 day ago - AMD To Rally More Than 36%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
- 1 day ago - Exelixis Catapults 14% On Positive Results For Next-Gen Colon Cancer Drug - Investor's Business Daily
- 2 days ago - Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer - Business Wire
- 4 days ago - Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors - Business Wire